论文部分内容阅读
Accentia生物制药公司 (Accentia Biopharmaceuticals Inc)于1月10日称,一种实验性疫苗似乎有助于缓解期非霍奇金淋巴瘤(NHL)患者维持缓解状态。该公司在上个月的美国血液学会会议上曾报告过BiovaxID疫苗的令人鼓舞的中期研究阶段的长期随访数据。在研究中,滤泡性 B细胞NHL化疗后缓解6个月的
Accentia Biopharmaceuticals Inc. on January 10 said that an experimental vaccine appears to help remission in patients with non-Hodgkin’s lymphoma (NHL). The company reported long-term follow-up data for the encouraging mid-term phase of the BiovaxID vaccine at the American Society of Hematology last month. In the study, follicular B-cell NHL was relieved 6 months after chemotherapy